Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Genomics. 2021 Mar;113(2):795-804. doi: 10.1016/j.ygeno.2021.01.021. Epub 2021 Jan 29.
RNA-binding proteins (RBPs) play crucial roles in multiple cancers. However, very few RBPs and their association with immune genes have been systematically studied in liver cancer (LC). We aimed to identify an immune-related RBP signature to predict the survival of LC patients. Bioinformatics methods were used to identify differentially expressed, immune-related, and prognostic RBPs and to develop an immune-related RBP signature based on data from the Cancer Genome Atlas (TCGA) cohort. We obtained eight differentially expressed, immune-related, and prognostic RBPs to construct a risk signature. The signature could effectively distinguish between high- and low-risk patients, and its predictive capacity was validated in the International Cancer Genomics Consortium (ICGC) cohort. We speculated that the high-risk group was more sensitive to targeted therapy. The immune-related RBP signature is an independent prognostic biomarker for LC patients and can expand the application of targeted therapy through patient stratification.
RNA 结合蛋白（RBPs）在多种癌症中发挥着关键作用。然而，在肝癌（LC）中，仅有很少的 RBPs 及其与免疫基因的关联得到了系统研究。我们旨在鉴定一种与免疫相关的 RBP 特征，以预测 LC 患者的生存情况。本研究采用生物信息学方法，从癌症基因组图谱（TCGA）队列中筛选差异表达、免疫相关且具有预后价值的 RBPs，并构建基于免疫相关 RBP 的特征。我们获得了 8 个差异表达、免疫相关且具有预后价值的 RBPs，用于构建风险特征。该特征可有效区分高低风险患者，在国际癌症基因组联合会（ICGC）队列中得到了验证。我们推测高危组对靶向治疗更敏感。与免疫相关的 RBP 特征是 LC 患者的独立预后生物标志物，可通过患者分层扩大靶向治疗的应用。
